Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells

Ella Lineham; Graham J. Tizzard; Simon J. Coles; John Spencer; Simon J. Morley

doi:10.18632/oncotarget.24354

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells

Ella Lineham _, Graham J. Tizzard, Simon J. Coles, John Spencer and Simon J. Morley

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:14148-14159. https://doi.org/10.18632/oncotarget.24354

Metrics: PDF 2680 views | HTML 4765 views | ?

Abstract

Ella Lineham1, Graham J. Tizzard2, Simon J. Coles2, John Spencer3 and Simon J. Morley1

1Department of Biochemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, UK

2UK National Crystallography Service, School of Chemistry, University of Southampton, Highfield, Southampton, UK

3Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, Brighton, UK

Correspondence to:

Simon J. Morley, email: [email protected]

Keywords: cell signaling; migration; kinase; dual inhibitors

Received: December 19, 2017 Accepted: January 25, 2018 Epub: January 31, 2018 Published: March 06, 2018

ABSTRACT

The study of eukaryotic initiation factor 4E (eIF4E) is a key focus in cancer research due to its role in controlling the translation of tumour-associated proteins, that drive an aggressive migratory phenotype. eIF4E is a limiting component of the eIF4F complex which is a critical determinant for the translation of mRNAs. Mitogen-activated protein kinase interacting protein kinases (MNK1/2) phosphorylate eIF4E on Ser209, promoting the expression of oncogenic proteins, whereas mTORC1 phosphorylates and de-activates the eIF4E inhibitor, 4E-BP1, to release translational repression. Here we show that inhibiting these pathways simultaneously effectively slows the rate of cell migration in breast cancer cells. However, a molecular hybridisation approach using novel, cleavable dual MNK1/2 and PI3K/mTOR inhibiting hybrid agents was less effective at slowing cell migration.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24354

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells

Abstract